Terms: = Liver cancer AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
65 results:
1. Development of an efficient liposomal DOX delivery formulation for HCC therapy by targeting CK2α.
Zhao R; Cheng S; Bai X; Zhang D; Fang H; Che W; Zhang W; Zhou Y; Duan W; Liang Q; Xiao L; Nie G; Hou Y
Biotechnol J; 2024 Apr; 19(4):e2400050. PubMed ID: 38651271
[TBL] [Abstract] [Full Text] [Related]
2. Exosomal lncRNA HEIH, an essential communicator for hepatocellular carcinoma cells and macrophage M2 polarization through the miR-98-5p/STAT3 axis.
Ai JH; Wen YZ; Dai SJ; Zhang LD; Huang ZJ; Shi J
J Biochem Mol Toxicol; 2024 Apr; 38(4):e23686. PubMed ID: 38549433
[TBL] [Abstract] [Full Text] [Related]
3. MicroRNA let-7c-5p Alleviates in Hepatocellular Carcinoma by Targeting Enhancer of Zeste Homolog 2: A Study Intersecting Bioinformatic Analysis and Validated Experiments.
Lin T; Guo X; Du Q; Liu W; Zhong X; Wang S; Cao L
Crit Rev Immunol; 2024; 44(4):23-39. PubMed ID: 38505919
[TBL] [Abstract] [Full Text] [Related]
4. ezh2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract] [Full Text] [Related]
5. EMT-related gene risk model establishment for prognosis and drug treatment efficiency prediction in hepatocellular carcinoma.
Gao X; Yang C; Li H; Shao L; Wang M; Su R
Sci Rep; 2023 Nov; 13(1):20380. PubMed ID: 37990105
[TBL] [Abstract] [Full Text] [Related]
6. Development and validation of multi-omic prognostic signature of anoikis-related genes in liver hepatocellular carcinoma.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Nov; 102(46):e36190. PubMed ID: 37986299
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of the prognosis Prediction Ability of a Necroptosis-Related Gene Signature and its Relationship With the Hepatocellular Carcinoma Immune Microenvironment Using Bioinformatics Analysis and Experimental Validation.
Guan R; Mei J; Guo R
Technol Cancer Res Treat; 2023; 22():15330338231182208. PubMed ID: 37335078
[No Abstract] [Full Text] [Related]
8. FGFR4 and ezh2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
[TBL] [Abstract] [Full Text] [Related]
9. CBX2-mediated suppression of SIAH2 triggers WNK1 accumulations to promote glycolysis in hepatocellular carcinoma.
Xu Z; Wu Y; Yang M; Wei H; Pu J
Exp Cell Res; 2023 May; 426(1):113513. PubMed ID: 36780970
[TBL] [Abstract] [Full Text] [Related]
10. Identification of cell senescence molecular subtypes in prediction of the prognosis and immunotherapy of hepatitis B virus-related hepatocellular carcinoma.
Yu X; Chen P; Yi W; Ruan W; Xiong X
Front Immunol; 2022; 13():1029872. PubMed ID: 36275676
[TBL] [Abstract] [Full Text] [Related]
11. Predicting the prognosis of hepatocellular carcinoma based on the interaction between pyroptosis, apoptosis, and necroptosis.
Qian F; Kong W; Wang S; Wei K
Clin Exp Med; 2023 Oct; 23(6):2087-2104. PubMed ID: 36271962
[TBL] [Abstract] [Full Text] [Related]
12. Construction of a Novel Oxidative Stress Response-Related Gene Signature for Predicting the prognosis and Therapeutic Responses in Hepatocellular Carcinoma.
Hong J; Cai X
Dis Markers; 2022; 2022():6201987. PubMed ID: 36133439
[TBL] [Abstract] [Full Text] [Related]
13. Dysregulation of ezh2/miR-138-5p Axis Contributes to Radiosensitivity in Hepatocellular Carcinoma Cell by Downregulating Hypoxia-Inducible Factor 1 Alpha (HIF-1
Bai B; Liu Y; Fu XM; Qin HY; Li GK; Wang HC; Sun SL
Oxid Med Cell Longev; 2022; 2022():7608712. PubMed ID: 36071871
[TBL] [Abstract] [Full Text] [Related]
14. lncRNA-AC079061.1/VIPR1 axis may suppress the development of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.
Lin XH; Zhang DY; Liu ZY; Tang WQ; Chen RX; Li DP; Weng S; Dong L
J Transl Med; 2022 Aug; 20(1):379. PubMed ID: 36038907
[TBL] [Abstract] [Full Text] [Related]
15. Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT‒qPCR validation.
Guan R; Zou J; Mei J; Deng M; Guo R
BMC Cancer; 2022 Jul; 22(1):830. PubMed ID: 35907846
[TBL] [Abstract] [Full Text] [Related]
16. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in liver Hepatocellular Carcinoma.
He A; Huang Z; Wang J; Lu H; Zhang R; Wu L; Feng Q
Dis Markers; 2022; 2022():3968303. PubMed ID: 35855852
[TBL] [Abstract] [Full Text] [Related]
17. The correlation of ezh2 expression with the progression and prognosis of hepatocellular carcinoma.
Wu SY; Xie ZY; Yan LY; Liu XF; Zhang Y; Wang DA; Dong J; Sun HT
BMC Immunol; 2022 Jun; 23(1):28. PubMed ID: 35659256
[TBL] [Abstract] [Full Text] [Related]
18. High Expression of ezh2 Mediated by ncRNAs Correlates with Poor prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma.
Chen Z; Lin X; Wan Z; Xiao M; Ding C; Wan P; Li Q; Zheng S
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627262
[TBL] [Abstract] [Full Text] [Related]
19. Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib.
Salani F; Latarani M; Casadei-Gardini A; Gangadharannambiar P; Fornaro L; Vivaldi C; Pecora I; Massa V; Marisi G; Canale M; Ulivi P; Scartozzi M; Eccleston M; Masi G; Crea F
Epigenomics; 2022 May; 14(9):507-517. PubMed ID: 35473355
[TBL] [Abstract] [Full Text] [Related]
20. LINC00963: A potential cancer diagnostic and therapeutic target.
Xie Z; Zhong C; Shen J; Jia Y; Duan S
Biomed Pharmacother; 2022 Jun; 150():113019. PubMed ID: 35462329
[TBL] [Abstract] [Full Text] [Related]
[Next]
